On the public citation graph

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

https://doi.org/10.15252/emmm.201707567

0 signed · 159 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cpt.651openalex-snapshot

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment

inferredcites →https://doi.org/10.1002/ijc.10557openalex-snapshot

Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

inferredcites →https://doi.org/10.1002/ijc.28312openalex-snapshot

Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells

inferredcites →https://doi.org/10.1007/s00109-016-1453-9openalex-snapshot

Oncolytic viruses—immunotherapeutics on the rise

inferredcites →https://doi.org/10.1016/0167-5699(96)80606-2openalex-snapshot

The expanding universe of T-cell subsets: Th1, Th2 and more

inferredcites →https://doi.org/10.1016/j.cellimm.2008.08.007openalex-snapshot

Relationship between CD107a expression and cytotoxic activity

inferredcites →https://doi.org/10.1016/j.coi.2015.12.007openalex-snapshot

The urgent need to recover MHC class I in cancers for effective immunotherapy

inferredcites →https://doi.org/10.1016/j.jim.2008.02.008openalex-snapshot

Detection of metastatic colon cancer cells in sentinel nodes by flow cytometry

inferredcites →https://doi.org/10.1016/j.molimm.2005.03.007openalex-snapshot

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

inferredcites →https://doi.org/10.1016/j.molimm.2005.07.034openalex-snapshot

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

inferredcites →https://doi.org/10.1016/j.omto.2016.11.003openalex-snapshot

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

inferredcites →https://doi.org/10.1016/j.omto.2017.03.003openalex-snapshot

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

inferredcites →https://doi.org/10.1016/j.yexmp.2012.09.018openalex-snapshot

Oncosis: An important non-apoptotic mode of cell death

inferredcites →https://doi.org/10.1016/s1359-6446(05)03554-3openalex-snapshot

BiTEs: bispecific antibody constructs with unique anti-tumor activity

inferredcites →https://doi.org/10.1038/bjc.2015.481openalex-snapshot

Oncolytic viruses: finally delivering

inferredcites →https://doi.org/10.1038/gt.2014.2openalex-snapshot

Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood

inferredcites →https://doi.org/10.1038/icb.2016.126openalex-snapshot

Targeting cancer‐related inflammation in the era of immunotherapy

inferredcites →https://doi.org/10.1038/nmeth.1318openalex-snapshot

Enzymatic assembly of DNA molecules up to several hundred kilobases

inferredcites →https://doi.org/10.1038/onc.2010.335openalex-snapshot

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer

inferredcites →https://doi.org/10.1038/sj.cgt.7700542openalex-snapshot

Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes

inferredcites →https://doi.org/10.1053/j.seminoncol.2016.10.005openalex-snapshot

Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers

inferredcites →https://doi.org/10.1093/annonc/mdu342.17openalex-snapshot

A Phase 1 Study of Enadenotucirev, an Oncolytic Ad11/Ad3 Chimeric Group B Adenovirus, Administered Intravenously - Analysis of Dose Expansion and Repeat Cycle Cohorts in Patients with Metastatic Colorectal Cancer (Mcrc)

inferredcites →https://doi.org/10.1097/cji.0b013e318156750copenalex-snapshot

Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class

inferredcites →https://doi.org/10.1111/cas.12208openalex-snapshot

Telomelysin shows potent antitumor activity through apoptotic and non‐apoptotic cell death in soft tissue sarcoma cells

inferredcites →https://doi.org/10.1126/science.1158545openalex-snapshot

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

inferredcites →https://doi.org/10.1158/0008-5472.can-09-0547openalex-snapshot

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

inferredcites →https://doi.org/10.1158/0008-5472.can-16-1708openalex-snapshot

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy

inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-0612openalex-snapshot

FDA Approval: Blinatumomab

inferredcites →https://doi.org/10.1182/blood-2012-01-400515openalex-snapshot

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

inferredcites →https://doi.org/10.1182/blood-2013-02-485623openalex-snapshot

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

inferredcites →https://doi.org/10.1200/jco.2010.32.7270openalex-snapshot

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

inferredcites →https://doi.org/10.1371/journal.pone.0002409openalex-snapshot

Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer

inferredcites →https://doi.org/10.1371/journal.pone.0136417openalex-snapshot

Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome

inferredcites →https://doi.org/10.1371/journal.pone.0177810openalex-snapshot

Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes

inferredcites →https://doi.org/10.1517/14712598.2015.1044433openalex-snapshot

Arming oncolytic viruses to leverage antitumor immunity

inferredcites →https://doi.org/10.15252/emmm.201707567openalex-snapshot

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

inferredcites →https://doi.org/10.4049/jimmunol.176.12.7308openalex-snapshot

Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4123194openalex-extracted

An Oncolytic Vaccinia Virus Expressing EpCAM Bispecific T-Cell Engager Enhances Immune Response in Solid Tumors

inferred← citeshttps://doi.org/10.1002/jso.70075openalex-snapshot

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers

inferred← citeshttps://doi.org/10.1002/mabi.201700187openalex-snapshot

Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses

inferred← citeshttps://doi.org/10.1002/stem.3004openalex-snapshot

Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses

inferred← citeshttps://doi.org/10.1007/978-1-0716-0171-6_3openalex-snapshot

In Vitro Functional Assay Using Real-Time Cell Analysis for Assessing Cancer Immunotherapeutic Agents

inferred← citeshttps://doi.org/10.1007/978-1-4939-9794-7_17openalex-snapshot

Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity

inferred← citeshttps://doi.org/10.1007/978-1-4939-9794-7_21openalex-snapshot

Mathematical Modeling of Oncolytic Virotherapy

inferred← citeshttps://doi.org/10.1007/978-3-030-21477-7_3openalex-snapshot

Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer

inferred← citeshttps://doi.org/10.1007/s11030-021-10326-zopenalex-snapshot

Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries

inferred← citeshttps://doi.org/10.1007/s12032-025-02746-wopenalex-snapshot

The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches

inferred← citeshttps://doi.org/10.1007/s40259-019-00367-0openalex-snapshot

Oncolytic Viruses: Priming Time for Cancer Immunotherapy

inferred← citeshttps://doi.org/10.1016/b978-0-323-89821-8.00007-3openalex-snapshot

Oncolytic adenovirus: Challenges and advancements of clinical translation

inferred← citeshttps://doi.org/10.1016/bs.acr.2026.02.006openalex-snapshot

Advancing clinical translation of oncolytic adenoviruses

inferred← citeshttps://doi.org/10.1016/bs.mie.2019.05.017openalex-snapshot

Genetic modification of oncolytic viruses to enhance antitumor immunity

inferred← citeshttps://doi.org/10.1016/bs.pmbts.2019.06.015openalex-snapshot

Synergistic combination of oncolytic virotherapy with CAR T-cell therapy

inferred← citeshttps://doi.org/10.1016/j.bbadis.2023.166962openalex-snapshot

Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status

inferred← citeshttps://doi.org/10.1016/j.bbcan.2024.189110openalex-snapshot

A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment

inferred← citeshttps://doi.org/10.1016/j.canlet.2026.218417openalex-snapshot

Bispecific T-cell engager therapy for gastrointestinal cancers

inferred← citeshttps://doi.org/10.1016/j.copbio.2019.11.016openalex-snapshot

Design and application of oncolytic viruses for cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.105039openalex-snapshot

Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology

inferred← citeshttps://doi.org/10.1016/j.ctarc.2021.100473openalex-snapshot

Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.ctarc.2026.101449openalex-snapshot

Oncolytic virotherapy at the tumor microenvironment–CAR Therapy interface: Mechanisms, clinical translation, and future directions

inferred← citeshttps://doi.org/10.1016/j.ctrv.2018.04.002openalex-snapshot

Bispecific antibodies in haematological malignancies

inferred← citeshttps://doi.org/10.1016/j.cytogfr.2020.07.004openalex-snapshot

Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment

inferred← citeshttps://doi.org/10.1016/j.esmoop.2020.100046openalex-snapshot

Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy

inferred← citeshttps://doi.org/10.1016/j.jconrel.2023.04.048openalex-snapshot

Multi-targeted immunotherapeutics to treat B cell malignancies

inferred← citeshttps://doi.org/10.1016/j.jmaa.2022.126278openalex-snapshot

Hopf bifurcation without parameters in deterministic and stochastic modeling of cancer virotherapy, part I

inferred← citeshttps://doi.org/10.1016/j.omto.2019.01.008openalex-snapshot

Updates on Oncolytic Virus Immunotherapy for Cancers

inferred← citeshttps://doi.org/10.1016/j.omto.2019.09.003openalex-snapshot

Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation

inferred← citeshttps://doi.org/10.1016/j.omto.2021.05.002openalex-snapshot

Current strategies in engaging oncolytic viruses with antitumor immunity

inferred← citeshttps://doi.org/10.1016/j.omto.2021.11.011openalex-snapshot

A one-step construction of adenovirus (OSCA) system using the Gibson DNA Assembly technology

inferred← citeshttps://doi.org/10.1016/j.omto.2021.11.014openalex-snapshot

Current development in adenoviral vectors for cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/j.omto.2023.08.011openalex-snapshot

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer

inferred← citeshttps://doi.org/10.1016/j.omton.2024.200821openalex-snapshot

DARPin-fused T cell engager for adenovirus-mediated cancer therapy

inferred← citeshttps://doi.org/10.1016/j.omton.2025.201017openalex-snapshot

An αvβ6-specific virotherapy expressing bispecific immune cell activators induces immune cell activation to mediate tumor cell death

inferred← citeshttps://doi.org/10.1016/j.omton.2025.201106openalex-snapshot

Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2023.108521openalex-snapshot

Potential targeting of the tumor microenvironment to improve cancer virotherapy

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2024.108611openalex-snapshot

Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations

inferred← citeshttps://doi.org/10.1016/j.trsl.2021.04.008openalex-snapshot

Development of oncolytic viruses for cancer therapy

inferred← citeshttps://doi.org/10.1016/j.ymthe.2018.04.001openalex-snapshot

Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones

inferred← citeshttps://doi.org/10.1021/acsinfecdis.8b00144openalex-snapshot

Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy

inferred← citeshttps://doi.org/10.1038/s41392-023-01407-6openalex-snapshot

Oncolytic virotherapy: basic principles, recent advances and future directions

inferred← citeshttps://doi.org/10.1038/s41392-026-02895-yopenalex-snapshot

Hypoxia increases the activity of oncolytic adenoviruses through HIF-2α-stimulated E1A expression

inferred← citeshttps://doi.org/10.1038/s41417-018-0042-1openalex-snapshot

Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference

inferred← citeshttps://doi.org/10.1038/s41417-020-00227-yopenalex-snapshot

Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer

inferred← citeshttps://doi.org/10.1038/s41423-020-0417-8openalex-snapshot

Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

inferred← citeshttps://doi.org/10.1038/s41467-017-02707-6openalex-snapshot

Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control

inferred← citeshttps://doi.org/10.1038/s41568-018-0009-4openalex-snapshot

Oncolytic viruses as engineering platforms for combination immunotherapy

inferred← citeshttps://doi.org/10.1038/s41573-019-0029-0openalex-snapshot

Optimizing oncolytic virotherapy in cancer treatment

inferred← citeshttps://doi.org/10.1038/s44321-024-00187-yopenalex-snapshot

Oncolytic viruses expressing MATEs facilitate target-independent T-cell activation in tumors

inferred← citeshttps://doi.org/10.1080/14712598.2019.1595582openalex-snapshot

Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

inferred← citeshttps://doi.org/10.1080/14712598.2020.1729351openalex-snapshot

Combination therapy with oncolytic viruses and immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1080/14756366.2019.1613987openalex-snapshot

Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

inferred← citeshttps://doi.org/10.1080/19420862.2021.1982447openalex-snapshot

Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics

inferred← citeshttps://doi.org/10.1080/2162402x.2018.1503032openalex-snapshot

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

inferred← citeshttps://doi.org/10.1080/2162402x.2022.2096362openalex-snapshot

Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer

inferred← citeshttps://doi.org/10.1080/21645515.2023.2256904openalex-snapshot

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer

inferred← citeshttps://doi.org/10.1089/hum.2017.145openalex-snapshot

Immuno-Oncology—The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets

inferred← citeshttps://doi.org/10.1093/immadv/ltad013openalex-snapshot

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment

inferred← citeshttps://doi.org/10.1111/imm.13323openalex-snapshot

Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity

inferred← citeshttps://doi.org/10.1136/jitc-2020-001191openalex-snapshot

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

inferred← citeshttps://doi.org/10.1136/jitc-2020-001292openalex-snapshot

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy

inferred← citeshttps://doi.org/10.1136/jitc-2021-002454openalex-snapshot

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy

inferred← citeshttps://doi.org/10.1136/jitc-2021-003645openalex-snapshot

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

inferred← citeshttps://doi.org/10.1136/jitc-2022-006518openalex-snapshot

Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?

inferred← citeshttps://doi.org/10.1136/jitc-2023-008460openalex-snapshot

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells

inferred← citeshttps://doi.org/10.1146/annurev-virology-012220-023606openalex-snapshot

A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies

inferred← citeshttps://doi.org/10.1158/0008-5472.can-18-1750openalex-snapshot

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-17-2651openalex-snapshot

Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-1565openalex-snapshot

Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-18-0297openalex-snapshot

CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment

inferred← citeshttps://doi.org/10.1186/s12935-022-02774-wopenalex-snapshot

Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?

inferred← citeshttps://doi.org/10.1186/s12943-020-01275-6openalex-snapshot

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

inferred← citeshttps://doi.org/10.1186/s12967-023-04360-8openalex-snapshot

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy

inferred← citeshttps://doi.org/10.1186/s13045-020-00922-1openalex-snapshot

Oncolytic viruses for cancer immunotherapy

inferred← citeshttps://doi.org/10.1186/s13045-021-01075-5openalex-snapshot

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

inferred← citeshttps://doi.org/10.1186/s13045-021-01164-5openalex-snapshot

Combination strategies to maximize the benefits of cancer immunotherapy

inferred← citeshttps://doi.org/10.1186/s13568-022-01422-wopenalex-snapshot

Preparation and identification of a single domain antibody specific for adenovirus vectors and its application to the immunoaffinity purification of adenoviruses

inferred← citeshttps://doi.org/10.1186/s40425-018-0350-xopenalex-snapshot

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells

inferred← citeshttps://doi.org/10.1186/s40425-019-0505-4openalex-snapshot

Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

inferred← citeshttps://doi.org/10.1186/s40425-019-0510-7openalex-snapshot

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

inferred← citeshttps://doi.org/10.1186/s40425-019-0807-6openalex-snapshot

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples

inferred← citeshttps://doi.org/10.1371/journal.pcbi.1014533openalex-snapshot

In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol

inferred← citeshttps://doi.org/10.15252/emmm.201911496openalex-snapshot

Live vaccines—a short‐cut to cancer viro‐immunotherapy

inferred← citeshttps://doi.org/10.21037/cco.2018.04.04openalex-snapshot

The emerging role of oncolytic virus therapy against cancer

inferred← citeshttps://doi.org/10.2147/dddt.s151282openalex-snapshot

Bispecific antibodies: design, therapy, perspectives

inferred← citeshttps://doi.org/10.2147/ijn.s164542openalex-snapshot

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

inferred← citeshttps://doi.org/10.2217/fon-2019-0606openalex-snapshot

Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy

inferred← citeshttps://doi.org/10.3389/fimmu.2018.00866openalex-snapshot

Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer

inferred← citeshttps://doi.org/10.3389/fimmu.2020.00683openalex-snapshot

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

inferred← citeshttps://doi.org/10.3389/fimmu.2022.1012806openalex-snapshot

Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses

inferred← citeshttps://doi.org/10.3389/fimmu.2022.1017574openalex-snapshot

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors

inferred← citeshttps://doi.org/10.3389/fimmu.2022.1029269openalex-snapshot

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer

inferred← citeshttps://doi.org/10.3389/fimmu.2023.1291836openalex-snapshot

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

inferred← citeshttps://doi.org/10.3389/fimmu.2023.1308890openalex-snapshot

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

inferred← citeshttps://doi.org/10.3389/fimmu.2024.1343378openalex-snapshot

Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy

inferred← citeshttps://doi.org/10.3389/fimmu.2025.1679092openalex-snapshot

Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives

inferred← citeshttps://doi.org/10.3389/fmicb.2023.1282112openalex-snapshot

Molecular biology of canine parainfluenza virus V protein and its potential applications in tumor immunotherapy

inferred← citeshttps://doi.org/10.3389/fmmed.2023.1140977openalex-snapshot

Cancer immunotherapies: A hope for the uncurable?

inferred← citeshttps://doi.org/10.3389/fonc.2020.561372openalex-snapshot

Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses

inferred← citeshttps://doi.org/10.3389/fonc.2022.772659openalex-snapshot

Role of Adenoviruses in Cancer Therapy

inferred← citeshttps://doi.org/10.3390/biomedicines8070204openalex-snapshot

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

inferred← citeshttps://doi.org/10.3390/cancers10080244openalex-snapshot

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics

inferred← citeshttps://doi.org/10.3390/cancers12040798openalex-snapshot

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase

inferred← citeshttps://doi.org/10.3390/cancers12041034openalex-snapshot

Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses

inferred← citeshttps://doi.org/10.3390/cancers12051295openalex-snapshot

Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination

inferred← citeshttps://doi.org/10.3390/cancers12061504openalex-snapshot

Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity

inferred← citeshttps://doi.org/10.3390/cancers12113354openalex-snapshot

Oncolytic Adenovirus in Cancer Immunotherapy

inferred← citeshttps://doi.org/10.3390/cancers13020287openalex-snapshot

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

inferred← citeshttps://doi.org/10.3390/cancers13040719openalex-snapshot

Tackling HLA Deficiencies Head on with Oncolytic Viruses

inferred← citeshttps://doi.org/10.3390/cancers14030624openalex-snapshot

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

inferred← citeshttps://doi.org/10.3390/ijms22052517openalex-snapshot

Oncolytic Adenoviruses for Cancer Therapy

inferred← citeshttps://doi.org/10.3390/ijms22169051openalex-snapshot

Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules

inferred← citeshttps://doi.org/10.3390/pathogens11101146openalex-snapshot

Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy

inferred← citeshttps://doi.org/10.3390/pharmaceutics14091811openalex-snapshot

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

inferred← citeshttps://doi.org/10.3390/v9090239openalex-snapshot

Fighting Cancer with Mathematics and Viruses

inferred← citeshttps://doi.org/10.34238/tnu-jst.6502openalex-snapshot

ĐẶC ĐIỂM SINH HỌC VÀ CHIẾN LƯỢC TĂNG HOẠT ĐỘNG CỦA ADENOVIRUS ĐỂ GÂY TAN TẾ BÀO UNG THƯ

inferred← citeshttps://doi.org/10.5603/ocp.98901openalex-snapshot

Double hit — bispecific antibodies in cancer therapy

inferred← citeshttps://doi.org/10.59717/j.xinn-med.2026.100216openalex-snapshot

Viral immunotherapy: Oncolytic approaches for solid tumors

inferred← citeshttps://doi.org/10.6084/m9.figshare.13219295openalex-snapshot

Additional file 1 of Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

inferred← citeshttps://doi.org/10.70675/6b8b8b92zda75z46a0z98e6zc9f888cb9715openalex-snapshot

T immune responses to SARS-CoV-2 : identification of the immunogenic region associated with protection against infection

showing the first 121 of 122

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.